Food and pharma demand for green packaging transforms the flexible packaging coatings market
Price concerns regarding sustainable coatings will be countered by their environmental and durability benefits, finds Frost & Sullivan.
The flexible packaging coatings market is set to witness robust growth due to the increasing need to enhance the shelf life of products in the North American food and pharmaceutical industry. Packaging coatings for the food segment holds the largest market trailed by the pharmaceutical sector. The latter trails as a result of the stringent regulations and long duration taken for product launch, making pharmaceuticals a less ventured sector. Rising consumer preference for lightweight products and the need to improve the quality of packaged contents are opening new avenues for market expansion of flexible packaging coatings.
Recent analysis from Frost & Sullivan, North American Flexible Packaging Coatings for the Food and the Pharmaceuticals Markets, finds that the market earned revenues of $1.44 billion in 2014 and estimates this to reach $1.97 billion in 2021. The study covers heat seal coatings, cold seal coatings, barrier coatings, co-extrusion primers and functional additives.
The enhanced efficiency, recyclability and composability of sustainable coatings will make green packaging a feasible option for North American market participants. Higher adaptation of sustainable coatings is observed throughout the forecast period. Thus, in place of solvent-based resins, formulators are turning to bio-based alternatives to develop flexible packaging coating solutions.
“Approximately 50 percent of the US population aged between 18 and 35 prefers to purchase products with labels that declare them to be environment friendly,” said Frost & Sullivan Visionary Science Team Leader Nandhini Rajagopal. “As this section of the population is willing to pay a premium for products with recyclable packaging.”
The price value offered by packaging coatings has encouraged cost conscious integrated packaging providers and pure players to adapt the product. Technological innovations in flexible packaging coatings such as ultra-thin coatings using nanotechnology and bio-based solutions offer significant growth opportunities. These coatings provide superior barrier protection as well as help in lowering the packaging layers, thus providing comprehensive quality and convenience.
“Evidently, novel flexible packaging coatings with an attractive price-performance ratio and innovative customer support services are key differentiators in the highly competitive and fragmented market,” summed up Rajagopal. “With the growing presence of participants with specialized product development capabilities and the need for heavy investments in R&D set-ups for innovation, tier 1 participants will enjoy considerable opportunities for mergers and acquisitions.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.